GLP-1 RAs and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Older Patients With Diabetes

IF 9.2 1区医学 Q1 OPHTHALMOLOGY

JAMA ophthalmology Pub Date : 2025-07-31 DOI:10.1001/jamaophthalmol.2025.2299

Kin Wah Fung, Fitsum Baye, Seo H. Baik, Clement J. McDonald

引用次数: 0

Abstract

This observational cohort study assesses the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on the incidence of nonarteritic anterior ischemic optic neuropathy in older patients with type 2 diabetes.

查看原文本刊更多论文

GLP-1 RAs与老年糖尿病患者非动脉性前缺血性视神经病变的风险

本观察性队列研究评估了胰高血糖素样肽-1受体激动剂（GLP-1 RA）对老年2型糖尿病患者非动脉性前缺血性视神经病变发生率的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA ophthalmology OPHTHALMOLOGY-

CiteScore

13.20

自引率

3.70%

发文量

340

期刊介绍： JAMA Ophthalmology, with a rich history of continuous publication since 1869, stands as a distinguished international, peer-reviewed journal dedicated to ophthalmology and visual science. In 2019, the journal proudly commemorated 150 years of uninterrupted service to the field. As a member of the esteemed JAMA Network, a consortium renowned for its peer-reviewed general medical and specialty publications, JAMA Ophthalmology upholds the highest standards of excellence in disseminating cutting-edge research and insights. Join us in celebrating our legacy and advancing the frontiers of ophthalmology and visual science.